PhaseWell Research has acquired Chase Medical Research to expand clinical trial capabilities and healthcare research access in Connecticut, strengthening its presence in the Northeast and enhancing support for cardiometabolic and central nervous system studies.  The Nashville-based clinical research company announced the acquisition as part of its strategy to increase participation in clinical trials through community-based sites. Chase Medical Research operates locations in Waterbury and Hamden and is led by founder and lead Principal Investigator Dr. Joseph Soufer.

"Chase Medical Research's 20+ years driving advances within cardiometabolic research exemplifies the type of community-based research sites we seek to partner with,” said Carsten Bick, Chief Executive Officer, PhaseWell Research

The addition expands PhaseWell’s cardiometabolic capabilities and complements its growing central nervous system research portfolio. Chase Medical Research brings experience across endocrine, cardiovascular, neurological, respiratory, and other health conditions, along with established connections to diverse patient populations in Connecticut.  The partnership supports PhaseWell’s broader goal of building a network of research sites capable of conducting Phase I through Phase IV clinical trials across multiple therapeutic areas.

“We look forward to this next chapter with PhaseWell. The partnership allows us to grow our sites and extend our reach while staying grounded in the Connecticut communities we serve,” said Dr. Soufer. “We are creating more opportunities to bring innovative clinical trials to patients in Connecticut while taking Chase Medical’s expertise outside our four walls to bring best-in-class cardiometabolic capabilities across PhaseWell’s growing national presence.”